Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Yasuharu Nakashima, Masakazu Kondo, Eisuke Shono, Takashi Ishinishi, Hiroshi Tsukamoto, Koji Kuroda, Akira Maeyama, Hiroshi Harada, Masayuki Maekawa, Takashi Shimauchi, Ryuji Nagamine, Hiroshi Jojima, Seiji Yoshizawa, Tomomi Tsuru, Takeshi Otsuka, Hisaaki Miyahara, Eiichi Suematsu, Ken Wada, Shigeru Yoshizawa, Yasushi Inoue, Takaaki Fukuda, Satoshi Ikemura & Akihisa Haraguchi. (2020) Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice. Modern Rheumatology 30:5, pages 807-815.
Read now
Read now
Masakazu Kondo & Hisakata Yamada. (2019) Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan. Modern Rheumatology 29:6, pages 928-935.
Read now
Read now
Takahito Suto, Yukio Yonemoto, Koichi Okamura, Hideo Sakane, Kimihiko Takeuchi, Yasuyuki Tamura, Tetsuya Kaneko, Keio Ayabe & Hirotaka Chikuda. (2019) The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Modern Rheumatology 29:5, pages 775-781.
Read now
Read now
Katsuhiko Takabayashi, Fumihiko Ando & Takahiro Suzuki. (2019) Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Modern Rheumatology 29:1, pages 87-97.
Read now
Read now
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi & Shigeki Makino. (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology 28:2, pages 227-234.
Read now
Read now
Yasuharu Nakashima, Hisaaki Miyahara, Masakazu Kondo, Takaaki Fukuda, Hiroshi Harada, Akihisa Haraguchi, Yasushi Inoue, Takashi Ishinishi, Masayuki Maekawa, Akira Maeyama, Munetoshi Nakashima, Eisuke Shono, Eiichi Suematsu, Takashi Shimauchi, Tomomi Tsuru, Hiroshi Tsukamoto, Shigeru Yoshizawa, Seiji Yoshizawa & Yukihide Iwamoto. (2017) Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses. Modern Rheumatology 27:1, pages 15-21.
Read now
Read now
Yasuhiko Hirabayashi, Yasuhiko Munakata, Masayuki Miyata, Yukitomo Urata, Koichi Saito, Hiroshi Okuno, Masaaki Yoshida, Takao Kodera, Ryu Watanabe, Seiya Miyamoto, Tomonori Ishii, Shigeshi Nakazawa, Hiromitsu Takemori, Takanobu Ando, Takashi Kanno, Masataka Komagamine, Ichiro Kato, Yuichi Takahashi, Atsushi Komatsuda, Kojiro Endo, Chihiro Murai, Yuya Takakubo, Takao Miura, Yukio Sato, Kazunobu Ichikawa, Tsuneo Konta, Noriyuki Chiba, Tai Muryoi, Hiroko Kobayashi, Hiroshi Fujii, Yukio Sekiguchi, Akira Hatakeyama, Ken Ogura, Hirotake Sakuraba, Tomoyuki Asano, Hiroshi Kanazawa, Eiji Suzuki, Satoshi Takasaki, Kenichi Asakura, Kota Sugisaki, Yoko Suzuki, Michiaki Takagi, Takahiro Nakayama, Hiroshi Watanabe, Keiki Miura & Yu Mori. (2016) Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group. Modern Rheumatology 26:6, pages 828-835.
Read now
Read now
Yasuharu Nakashima, Masakazu Kondo, Hisaaki Miyahara & Yukihide Iwamoto. (2014) Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab. Drug Design, Development and Therapy 8, pages 913-919.
Read now
Read now
Articles from other publishers (12)
Patrick J. Krohl, Justyn Fine, Huilin Yang, Derek VanDyke, Zhiwei Ang, Kook Bum Kim, Andrei Thomas-Tikhonenko & Jamie B. Spangler. (2023) Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach. Cell Reports Methods 3:3, pages 100429.
Crossref
Crossref
Huilin Yang, Michelle N. Karl, Wentao Wang, Bartholomew Starich, Haotian Tan, Ashley Kiemen, Alexandra B. Pucsek, Yun-Huai Kuo, Gabriella C. Russo, Tim Pan, Elizabeth M. Jaffee, Elana J. Fertig, Denis Wirtz & Jamie B. Spangler. (2022) Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. Molecular Therapy 30:11, pages 3430-3449.
Crossref
Crossref
Javier Narváez, Teresa Oton, Judit Lluch, Maribel Mora-Limiñana, Joan Miquel Nolla & Estíbaliz Loza. (2022) La réponse aux antagonistes du récepteur de l’interleukine-6 dans la polyarthrite rhumatoïde est indépendante du nombre d’anti-TNF administrés auparavant : revue systématique et méta-analyse. Revue du Rhumatisme 89:1, pages 11-23.
Crossref
Crossref
Javier Narváez, Teresa Oton, Judit LLuch, Maribel Mora-Limiñana, Joan Miquel Nolla & Estíbaliz Loza. (2021) Response to interleukin-6 receptor antagonists in patients with rheumatoid arthritis is independent of the number of prior used TNF inhibitors: A systematic review and metaanalysis. Joint Bone Spine 88:1, pages 105112.
Crossref
Crossref
Michele Russell-Westhead, Nicola O’Brien, Iain Goff, Elizabeth Coulson, Jess Pape & Fraser Birrell. (2020) Mixed methods study of a new model of care for chronic disease: co-design and sustainable implementation of group consultations into clinical practice. Rheumatology Advances in Practice 4:1.
Crossref
Crossref
Khaled Algohani, Muhannad Althobaiti, Sanad Alshammari, Fahad Alnahari, Ali Aldahhasi & Feras Habshan. (2019) The outcome of patients with rheumatoid arthritis: a cross-sectional study. International Journal of Medicine in Developing Countries, pages 5-9.
Crossref
Crossref
Takayasu Ando, Takeshi Suzuki, Yutaka Gotou, Mitsuru Imamura, Hiroko Nagafuchi, Yoshioki Yamasaki, Seido Ooka & Kimito Kawahata. (2019) Early Response of DAS28-ESR (3) Predicts Sustained Response to Tocilizumab Switched from Abatacept. Journal of St. Marianna University 10:2, pages 39-49.
Crossref
Crossref
Gablu Kilcher, Noemi Hummel, Eva M Didden, Matthias Egger & Stephan Reichenbach. (2018) Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology 57:2, pages 354-369.
Crossref
Crossref
Elham Rajae, Ali Bidari, Jafar Forghani Zadeh, Arash Asilian & Shirin Azizidoost. (2017) The effect of tocilizumab on clinical signs and laboratory findings in rheumatoid arthritis patients resistant to methotrexate. Comparative Clinical Pathology 26:5, pages 1221-1226.
Crossref
Crossref
Hasini Jayatilaka, Pranay Tyle, Jonathan J. Chen, Minsuk Kwak, Julia Ju, Hyun Ji Kim, Jerry S. H. Lee, Pei-Hsun Wu, Daniele M. Gilkes, Rong Fan & Denis Wirtz. (2017) Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. Nature Communications 8:1.
Crossref
Crossref
Fabrizio Cantini, Carlotta Nannini, Laura Niccoli, Linda Petrone, Giuseppe Ippolito & Delia Goletti. (2017) Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation 2017, pages 1-15.
Crossref
Crossref
Vasco C. Romão, Maria José Santos, Joaquim Polido-Pereira, Cátia Duarte, Patrícia Nero, Cláudia Miguel, José António Costa, Miguel Bernardes, Fernando M. Pimentel-Santos, Filipe Barcelos, Lúcia Costa, José António Melo Gomes, José Alberto Pereira da Silva, Jaime Cunha Branco, José Canas da Silva, José António Pereira da Silva, João Eurico Fonseca & Helena Canhão. (2015) Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International 2015, pages 1-13.
Crossref
Crossref